FindTrial
Sign In

single dose of CNCT19

BIOLOGICAL6 trials

Sponsors

Juventas Cell Therapy Ltd.

Conditions

B-cell Acute Lymphoblastic LeukemiaDiffuse Non-Hodgkin LymphomaLupus Erythematosus, SystemicNon-Hodgkin's LymphomaRelapsed or Refractory Acute Lymphoblastic Leukemia

Early Phase 1

Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
RecruitingNCT06316791
Juventas Cell Therapy Ltd.Lupus Erythematosus, Systemic
Start: 2021-12-14End: 2025-12-13Target: 24Updated: 2025-02-10

Phase 1

A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
CompletedNCT04230473
Juventas Cell Therapy Ltd.Relapsed or Refractory Acute Lymphoblastic Leukemia
Start: 2020-03-13End: 2022-11-01Updated: 2023-03-28
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma
CompletedNCT04232826
Juventas Cell Therapy Ltd.Diffuse Non-Hodgkin Lymphoma
Start: 2020-01-15End: 2022-11-01Updated: 2023-03-28
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
RecruitingNCT05667506
Juventas Cell Therapy Ltd.B-cell Acute Lymphoblastic Leukemia
Start: 2023-02-07End: 2027-05-30Target: 47Updated: 2025-08-12

Phase 2

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
RecruitingNCT04586478
Juventas Cell Therapy Ltd.Non-Hodgkin's Lymphoma
Start: 2020-10-26End: 2025-09-30Target: 60Updated: 2025-02-07
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
RecruitingNCT04684147
Juventas Cell Therapy Ltd.Relapsed or Refractory Acute Lymphoblastic Leukemia
Start: 2020-12-24End: 2026-12-31Target: 100Updated: 2025-08-08

Related Papers

Synergistic integration of CAR-T cell pharmacokinetics and NGS-MRD evolution enables precision risk stratification in relapsed/refractory B-cell acute lymphoblastic leukemia
Blood2025-11-03
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia
Blood Advances2024-12-0310 citations
Efficacy and Safety of Inaticabtagene Autoleucel in Children with Relapsed/Refractory (R/R) B-cell Acute Lymphoblastic Leukemia in China
Blood2024-11-052 citations
Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China
Blood2024-11-051 citations
Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma
Journal for ImmunoTherapy of Cancer2024-04-0125 citations
Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China
Hematology Transfusion and Cell Therapy2023-10-013 citations
Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia.
2022-12-0112 citations
Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China
Blood2022-11-156 citations
CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study
Blood2022-11-151 citations